Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients
Scipher Medicine Signs Multi-Target Partnership with Ionis
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new data showing patients with rheumatoid arthritis (RA) whose treatment was informed by PrismRA had improved clinical outcomes and use of PrismRA could reduce health care spending. The data were published in Expert Opinion on Biological Therapy.
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities Life Sciences AI Symposium on Tuesday, March 1, 2022, at 10:10 a.m. ET.
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing. The round is led by Cowen Healthcare Investments, with participation from new investors Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management. Existing investors Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, and Alumni Ventures also are participating. To date, Scipher has raised $227 million.
Scipher’s PrismRA test analyzes each patient’s molecular signature to determine whether they’ll respond to tumor necrosis factor inhibitor, or TNFi, therapy. The drug class is prescribed to an estimated 90% of the 20 million RA patients around the world but is only clinically effective in about one-third of those prescribed, according to Scipher.
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Alif Saleh, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:30 a.m. ET.
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer.
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to PrismRA. PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).
Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of John Strumbos, Ph.D., MBA as Chief Financial Officer. John will be instrumental in guiding Scipher’s financing and capital strategy as the company continues its rapid growth trajectory.